Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Thursday 21 February, 2008

Summit Corporation PLC

Re Contract

Summit Corporation plc
("Summit plc" or "the Company")

* £500,000 GMP service contracts signed with potential total value
  over £1m
* New Director of Sales Appointed

Oxford, UK, 21 February 2008 - Summit Corporation plc (AIM: SUMM), a
leading UK biotechnology company, today announces that its specialist
carbohydrate chemistry subsidiary business, Dextra Laboratories, has
signed service contracts together worth an initial £500,000 with four
undisclosed biotechnology companies; the value of these deals could
rise to over £1 million over the next six months.

Dextra will use its world-leading expertise and know-how in
carbohydrate chemistry to develop efficient routes of compound
synthesis and GMP product supply for its client's drug development
and healthcare programmes.  The projects will be conducted at
Dextra's GMP facility in Reading, UK, which was completed in June
2007.  This capability proved to be a key factor in the signing of
these deals as it permits the Company to produce material suitable
for use in human clinical trials up to the Phase II stage of

Steven Lee, PhD, Chief Executive Officer of Summit plc commented:
"Carbohydrate chemistry is becoming an increasingly important area
for the discovery, development and manufacture of new and often
difficult to synthesise drugs and healthcare products.  Dextra offers
a world-class carbohydrate chemistry service and these deals
represent the first significant return on our investment in being GMP
accredited, a status that is giving us the edge in winning
higher-value contracts."

Appointment of Director of Sales

Separately, Summit is pleased to announce the appointment of James
Beaumont as Director of Sales at Dextra Laboratories to oversee the
Company's ambitious plans to deliver more substantial revenues from
its carbohydrate chemistry service business.

James was previously Vice President of Business Development at Evotec
and brings a wealth of chemistry sales experience to Dextra.  During
his time at Evotec, James delivered manufacturing, process and
development chemistry contracts worth in excess of ¤20 million in
addition to developing new business in process chemistry R&D, custom
synthesis and GMP plant manufacture with multi-national
pharmaceutical and biotechnology companies.   He has previously held
sales positions with the US biotechnology company Genzyme and the US
drug delivery technology company, Penwest Pharmaceuticals.

                              - ENDS -

For more information, please contact:

Summit plc
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951

Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible
Tel: +44 (0)207 638 9571

Panmure Gordon
Andrew Burnett / Rakesh Sharma
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a leading UK biotechnology company that discovers and
develops proprietary new drugs. The Company's internal drug
development programmes are underpinned by its advanced carbohydrate
chemistry and zebrafish drug screening technology platforms, which it
also provides on a collaborative or fee-for-service basis to the
pharmaceutical industry.
Summit plc has a broad range of drug discovery programmes in the
clinical, pre-clinical and discovery stages of development, which
target serious diseases with a high unmet medical need. These
therapeutic areas include neurological disorders, anti-infectives,
ophthalmic diseases and oncology.
Summit plc's in-house drug development capabilities combine
world-class expertise in both carbohydrate chemistry with
high-volume, high-content screening using its proprietary zebrafish
technologies. These whole organism screens have the potential to
dramatically decrease the time and cost of drug discovery and
development by delivering data that are highly predictive of the
efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in
October 2004 - symbol: SUMM

Further information about the company is available at